Cyclopharm Ltd (ASX: CYC) Share Price and News

Mr Heaney is currently the Chairman of Cyclopharm and Chairman of the Remuneration and Board Nomination Committees. He was formerly Chairman of the Audit and Risk Committee until 28 February 2019. Mr Heaney was re-appointed as acting Chairman of the Audit and Risk Committee effective 1 December 2021 until 18 February 2024. Mr Heaney has also served as a Non-Executive Director of several ASX-listed and non-listed companies. Mr Heaney has more than 40 years of experience in all aspects of wholesale banking and finance, gained in general management roles with National Australia Bank Limited and subsidiary companies in both Australia and the US.

Ms Angus is a member of the Risk Committee. Ms Angus has executive managerial and company director experience in the biotechnology, biopharmaceutical, medical device, agritech and healthcare industries. She has long been involved in path to market asset development and commercialization in these industries, notably including the clinical validation of therapeutics to create asset and company valuation uplift. Ms Angus has wide expertise in corporate strategy, stakeholder engagement and innovative product development together with governance and compliance experience in listed capital markets. Ms Angus has held directorship roles in several ASX and NASDAQ-listed companies and is currently Non-Executive Chair of Argenica Therapeutics and Non-Executive Director of Neuren Pharmaceuticals. She also serves as a council member of Deakin University and is a board member of Agriculture Victoria Services.

Mr McBrayer serves as a member of the Board Nominations Committee. Mr McBrayer has more than 30 years of experience in nuclear medicine and is a trained Nuclear Pharmacist. Mr McBrayer held the role of Managing Director at Lipa Pharmaceuticals, Australia's largest contract manufacturer of over-the-counter products and senior management positions with Brambles Cleanaway business and Syncor, the world's largest radioactive diagnostic and therapeutic pharmaceutical provider.

Mr Barrow is a member of the Risk Committee. He brings more than 20 years of experience in the healthcare industry, which includes governance and senior executive roles. Mr Barrow is currently the Chief Executive Officer of the Sydney North Health Network. Mr Barrow was the Chief Executive Officer of the Butterfly Foundation, Australia's national charity providing clinical services and support to address eating disorders and body image issues. Prior to this role, Mr Barrow was the Managing Director at Philips Australia and New Zealand overseeing all Philips' operations in the region, while also direct General Manager for the Healthcare division, a leader in cardiac care, acute care and home healthcare.

Mr King is a clinician and respiratory physiologist who brings over 25 years of experience as a clinician, educator and researcher to the Cyclopharm board. Dr. King is Professor of Respiratory Medicine at the Northern and Central Clinical Schools of the University of Sydney. He is also the Staff Specialist in the Department of Respiratory Medicine at Royal North Shore Hospital, where he directs the asthma service and is the Medical Director of the Respiratory Investigation Unit, and the Research Leader of the Airway Physiology and Imaging Group at the Woolcock Institute of Medical Research.

Mr Wigglesworth is a Chartered Accountant with 37 years professional experience, including 24 years as a Partner at KPMG both in Australia and internationally. During this time, he held several leadership positions across operations, industry sectors and business development. Mr Wigglesworth has experience working with ASX listed and leading global companies, with specific expertise in external and internal audit, financial reporting, accounting systems and controls, governance and risk management. Mr Wigglesworth has been appointed as Chairman of the Risk Committee and is a member of the Remuneration Committee and Board Nomination Committee effective 19 February 2024.